1. Patients with Atrial Fibrillation Switching Emphasis from stroke prevention to stroke and hemorrhage prevention.
Michael D. Ezekowitz, MBChB, DPhil,
FACC, FAHA, FRCP, MA
Professor, Sidney Kimmel Medical School at Thomas Jefferson University
Attending Cardiologist Lankenau Medical Center, Bryn Mawr, and Paoli hospitals
No Citation Given. 1

2. Disclosures
Michael D. Ezekowitz has received consulting fees from Boston Scientific , Boehringer Ingelheim, Pfizer, Sanofi, Bristol- Myers Squibb, Portola, Daiichi-Sankyo, Medtronic, Johnson & Johnson, and Janssen Scientific Affairs; grant support from Boehringer Ingelheim, Pfizer, and Bristol-Myers Squibb
Co-PI PETRO, RE-LY, X-VeRT, EMANATE; Executive Committee ENSURE-AF, ENGAGE-AF.

3. Left atrial appendage thrombus migration captured by TEE (Parekh…Ezekowitz Circ 06 )

5. Contraindication to oral anticoagulation Redfors B , Gray W , Lee R , Ellenbogen K, Bonefede M and Ben –Yehuda JACC EP 2017
1.3 million patients with the new diagnosis of AF from the Medicare and Supplemental insurance USA data base were identified
About 43, 000 were not receiving an anticoagulation because of a contra-indication defined as : History of hemorrhagic stroke; intracranial bleeding; intraocular bleeding Significant bleeding from the gastrointestinal, genitourinary, or respiratory tracts or the presence of aortic dissection or cerebral aneurysm not repaired at < 3 months
The annual risk of stroke of the 43, 000 were 7.7% ( 3.2 % hemorrhagic) , major bleeding 8.2% and dying was 12.7 %

6. Clinical Therapeutics 2003;25: No 6.
Factors Influencing Physician Use of Anticoagulation in Atrial Fibrillation
Physicians more influenced by events induced (bleeds) than those prevented (strokes)
The decision to use warfarin in NVAF is driven by perceived risks (intracerebral bleeds)
Gross CP, Vogel EW, Dhond, AJ, Marple CB, Edwards RA, Hauch O, Demers EA,
Ezekowitz MD. Factors Influencing Physician Use of Anticoagulation in Atrial Fibrillation.
Clinical Therapeutics 2003;25: No 6.

7. Country-Based Variation in TTR
Mean % time in therapeutic INR range 7

8. Major bleeding, treatment-independent (Kent …. Ezekowitz JACC 2018 )

9. Effect of NSAID use Stroke or systemic embolism, treatment-independent ( Kent … Ezekowitz JACC 2018 )

10. Major bleeding, treatment-dependent Kent … Ezekowitz ( Kent …
Major bleeding, treatment-dependent Kent … Ezekowitz ( Kent …. Ezekowitz JACC 2018 )

11. Stroke or systemic embolism (S/SE), treatment-dependent (Kent … Ezekowitz JACC 2018 )

12. © 2019- Private & Confidential
February 2019
TRANSFORMING HEALTHCARE WITH DIGITAL MEDICINES
© Private & Confidential

13. Digital Medicines Solve a Major Health Issue
Pharmaceutical Therapy Yields Uncertain Value For Patients, Providers and Payers
Global Pharmaceuticals
Consumers Don’t Take Their Drugs
Cost of Medication Non-Adherence At Least $500B Annually in U.S.
$1.2 trillion by 2022
$528 billion
Medication Possession Ratios (MPR)
Actual adherence likely 25% to 35%
Sources: Chronic conditions: making the case for ongoing care (Johns Hopkins University); Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions (Pharmacotherapy); Patient Adherence: The Next Frontier in Patient Care; Annals of Internal Medicine ; Nonadherence to antihypertensive drugs (American Heart Association); Nonadherence to antihypertensive drugs (Abegaz et al. Medicine 96:4)

14. Used by Healthcare Teams
Digital Medicines Ensure Drugs Work in the Real World
Proteus seamlessly combines drugs, devices, digital applications and data analytics
Did I take my drugs today?
How do my drugs affect my daily life?
Can my care team make the drug dose more specific?
Is my drug taking delivering the outcomes I want?
Used by Healthcare Teams
Used by Patients
Digital Medicines
Wearable Sensor
Patient Mobile App
Provider Web/EHR App

15. Enabled By A Unique Ingestible Sensor
The world’s smallest, safest, global regulator approved medical device
Drug Blend
Cleared by FDA, CFDA, CE Marked in Europe
Designed to be incorporated into medicines
Supported by technology and data platforms
Proteus Ingestible Sensor
Silicon: 0.9mg Bananas: 5mg
per 100 grams
Digital Medicine:
Ingestible sensors enable digital medicines
No change in size, shape or drug properties
Copper: 0.02mg Cashews: 2.2mg
per 100 grams
Magnesium: 0.01mg
Halibut: 107mg
per 100 grams